|Bid||146.50 x 1100|
|Ask||147.94 x 800|
|Day's Range||145.36 - 147.92|
|52 Week Range||115.92 - 170.75|
|Beta (5Y Monthly)||0.27|
|PE Ratio (TTM)||24.12|
|Earnings Date||Jan 29, 2021|
|Forward Dividend & Yield||2.96 (2.01%)|
|Ex-Dividend Date||Nov 12, 2020|
|1y Target Est||165.88|
Equillium (EQ) decides to not initiate a phase III study on its candidate, itolizumab, for the treatment of hospitalized COVID-19 patients at this time.
Dr. David Katz, Preventive Medicine Specialist & True Health Initiative President, joined Yahoo Finance Live to discuss the surging number of COVID-19 cases in the U.S. and how the Thanksgiving holiday may impact case numbers.